SYDNEY (Reuters) -Chinese biotech firm Duality Biotherapeutics launched an initial public offering (IPO) of up to HK$1.56 billion ($200.7 million) on Monday in Hong Kong, testing investor appetite ...

More than three-quarters of private biotech investment tracked by BioPharma Dive between January and March was distributed ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an IPO on the week of April 7th, IPO Scoop reports. The company plans to issue 2,700,000 shares at a price of $7.50-$8.50 ...

Explore Q1 2025's biotech stock moves, from CervoMed's 300% surge to Septerna's struggles. Click for my review of the quarter ...

This is also true for the sector’s IPO market. Compared to 2021, when many biotech IPOs were pre-clinical, sector IPOs today are more likely to be at the matured clinical stage, anticipating a ...

Jyong Biotech Ltd. (Revived IPO) (MENS) expects to raise $22 million in an initial public offering (IPO) on the week of April 7th, IPO Scoop reports. The company plans to issue 2,700,000 shares at ...

The share acquisition is the latest twist in a dispute between Alcon and fellow Aurion shareholder Deerfield Management over ...

The biotechnology sector is gaining new momentum with better market conditions, cutting-edge innovations, and growing ...

Though biotech IPOs have been quiet since 2021, industry experts believe that falling interest rates and favorable conditions for investments could reopen the IPO window for companies seeking ...

The maker of the FDA’s only approved total artificial heart has outlined plans to go public, with a $12 million IPO, ...

SYDNEY (Reuters) -China biotech firm Duality Biotherapeutics is testing investor appetite on Monday amid a global stock market rout by launching a HK$1.56 billion ($200.70 million) Hong Kong initial ...

To receive daily news and insights, subscribe to our free daily BioPharma Dive newsletter. Biotechnology company funding rounds remain larger than they were in 2022 and 2023, in a sign venture ...